Koshiishi Haruya, Takahashi Eisuke, Koseki Keita, Mori Kenichirou, Goto Hiroshi, Okamura Takashi, Minami Tomohito, Tamamoto Fumihiko, Sakaniwa Nobuyuki, Hayashi Naganobu, Koshiishi Yoshihiko
Dept. of Surgery, Tokyo Metropolitan Otsuka Hospital.
Gan To Kagaku Ryoho. 2007 Nov;34(12):2068-70.
Six high-risk patients of lung cancer with carcinomatous pleuritis to which BAI was done were examined. BAI was performed using CDDP (40-50 mg/m2) + CPT-11 (40-50 mg/m2). The therapeutic effects, side effects, a reduction of the symptoms and prognosis were examined.
All cases were revealed as stable disease according to the rule of the RECIST. The side effect of appetite loss for over grade 2 was found in one case. The reduction of respiratory symptoms (cough, dyspnea at the movement in 3, chest pain in 1 and loss of the movement in 1) was recognized by four out of five cases. Five patients died in three to seven months after the treatment of BAI. The causes of death were the recurrence of carcinomatous pleuritis and the primary lesion or the metastasis lesion of the lung in 4 cases and the recurrence of the primary lesion in 1 case. The recurrence of the malignant pleural effusion was recognized in 1 case without intra-thoracic infusion.
BAI was effective as a reduction of the respiratory symptoms in the high-risk patients of lung cancer with carcinomatous pleuritis. It appeared that a long-term survival was probable with the combination of BAI, intra-thoracic infusion and systemic chemotherapy.
